Oliger Christy J. 4

What Happened

• Christy J. Oliger, a director of Vera Therapeutics (VERA), was granted 17,084 derivative shares (transaction code A — award/grant) on 2026-05-21. The filing reports $0.00 consideration for the award (no cash paid). This is an equity grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-21; SEC filing date: 2026-05-26 (filed 5 days after the transaction; Form 4s are normally due within two business days, so this appears to be a late filing).
• Shares/amount: 17,084 shares granted; reported price/consideration: $0.00.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: The award vests in full on the earlier of (a) the first anniversary of the grant date or (b) the Company’s 2027 annual stockholder meeting, subject to continuous service. The award also fully vests upon a change in control, subject to continuous service.
• Transaction type: Derivative equity award (code A). No sale or open-market purchase was reported.

Context

• This is a standard equity grant to a director — it represents compensation rather than an investment purchase. Because it vests over time (one-year/meeting-based cliff with change-in-control acceleration), the grant rewards continued service rather than indicating immediate insider buying or selling.